Total Payments
$9,173
2024 Payments
$1,474
Companies
55
Transactions
462
Medicare Patients
17,119
Medicare Billing
$2.7M
Payment Breakdown by Category
Food & Beverage$8,448 (92.1%)
Education$724.43 (7.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,448 | 445 | 92.1% |
| Education | $724.43 | 17 | 7.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $956.04 | 47 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $693.35 | 35 | $0 (2024) |
| Amgen Inc. | $686.03 | 33 | $0 (2023) |
| Genentech USA, Inc. | $401.13 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $386.52 | 25 | $0 (2024) |
| GENZYME CORPORATION | $365.16 | 16 | $0 (2024) |
| Janssen Biotech, Inc. | $341.80 | 18 | $0 (2024) |
| Celgene Corporation | $304.91 | 16 | $0 (2024) |
| Incyte Corporation | $291.27 | 20 | $0 (2023) |
| Astellas Pharma US Inc | $289.70 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,474 | 60 | Merck Sharp & Dohme LLC ($152.97) |
| 2023 | $931.82 | 40 | Janssen Biotech, Inc. ($121.67) |
| 2022 | $293.39 | 14 | AVEO Pharmaceuticals, Inc. ($32.80) |
| 2020 | $405.14 | 24 | AstraZeneca Pharmaceuticals LP ($64.40) |
| 2019 | $3,043 | 150 | AstraZeneca Pharmaceuticals LP ($371.11) |
| 2018 | $2,618 | 146 | Amgen Inc. ($359.72) |
| 2017 | $407.25 | 28 | Genentech USA, Inc. ($75.41) |
All Payment Transactions
462 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.95 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $42.92 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.99 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.24 | General |
| Category: Hematology | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $28.58 | General |
| 10/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.24 | General |
| 10/15/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.50 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: BioOncology | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Oncology | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 5,390 | 188,138 | $1.5M | $677,627 |
| 2022 | 54 | 5,239 | 191,026 | $2.2M | $1.1M |
| 2021 | 50 | 3,295 | 110,549 | $914,133 | $434,853 |
| 2020 | 50 | 3,195 | 117,030 | $930,452 | $423,605 |
Total Patients
17,119
Total Services
606,743
Medicare Billing
$2.7M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 94 | 9,720 | $284,400 | $177,641 | 62.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 98 | 129,750 | $261,000 | $112,673 | 43.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 34 | 32,970 | $131,880 | $77,722 | 58.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 386 | 633 | $128,609 | $52,424 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 105 | 316 | $96,780 | $38,159 | 39.4% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 22 | 110 | $73,475 | $29,856 | 40.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 67 | 304 | $124,440 | $25,881 | 20.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 561 | 2,229 | $32,792 | $16,667 | 50.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 572 | 1,541 | $28,359 | $15,801 | 55.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 604 | 1,741 | $26,235 | $14,217 | 54.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $23,105 | $9,144 | 39.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 272 | 609 | $14,898 | $8,097 | 54.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 86 | 154 | $28,936 | $6,470 | 22.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 118 | $24,780 | $6,104 | 24.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 18 | 81 | $5,670 | $5,909 | 104.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 100 | $14,204 | $5,626 | 39.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 169 | 547 | $37,432 | $5,395 | 14.4% |
| 83550 | Iron binding capacity | Office | 2023 | 265 | 587 | $9,015 | $4,997 | 55.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $10,155 | $4,241 | 41.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 41 | 214 | $19,180 | $4,152 | 21.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 26 | 107 | $23,683 | $3,960 | 16.7% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 59 | 232 | $6,960 | $3,927 | 56.4% |
| 83540 | Iron level | Office | 2023 | 265 | 587 | $6,618 | $3,690 | 55.8% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 25 | 56 | $13,664 | $3,482 | 25.5% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 98 | 156 | $5,928 | $3,415 | 57.6% |
About Dr. Nnamdi Eze, MD
Dr. Nnamdi Eze, MD is a Hematology & Oncology healthcare provider based in Shelbyville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2008. The National Provider Identifier (NPI) number assigned to this provider is 1033370986.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nnamdi Eze, MD has received a total of $9,173 in payments from pharmaceutical and medical device companies, with $1,474 received in 2024. These payments were reported across 462 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($8,448).
As a Medicare-enrolled provider, Eze has provided services to 17,119 Medicare beneficiaries, totaling 606,743 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Shelbyville, TN
- Active Since 06/23/2008
- Last Updated 09/10/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1033370986
Products in Payments
- KEYTRUDA (Biological) $930.11
- JEVTANA (Drug) $386.14
- TAGRISSO (Drug) $211.05
- Kyprolis (Biological) $208.04
- FOTIVDA (Drug) $206.06
- OPDIVO (Biological) $205.64
- XTANDI (Drug) $201.97
- Neulasta (Biological) $201.04
- Lenvima (Drug) $194.94
- JAKAFI (Drug) $192.89
- GILOTRIF (Drug) $186.38
- ZEJULA (Drug) $166.27
- IMFINZI (Drug) $160.27
- TECENTRIQ (Biological) $154.16
- IBRANCE (Drug) $135.33
- Abraxane (Drug) $133.81
- SPRYCEL (Drug) $116.36
- LYNPARZA (Drug) $115.94
- Imbruvica (Drug) $113.64
- Enhertu (Drug) $109.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.